Company Overview
Snapshot
Founded in November 2016, SpliSense operates with 11–50 employees. The company has raised $54.5M across 5 funding rounds from 6 investors, including a recent investment from Cystic Fibrosis Foundation in June 2026. SpliSense focuses on developing RNA-based treatments for pulmonary diseases.
Business overview
SpliSense is a clinical-stage biotechnology company specializing in RNA-based treatments for pulmonary diseases, particularly those with a genetic basis. The company leverages Antisense Oligonucleotide (ASO) technology, delivered non-invasively via inhalation, to target the root cause of diseases by overcoming specific genetic mutations and modulating protein expression and function. SpliSense operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals, biotechnology, and drug development for unmet medical needs.
Strategic signal
In June 2026, SpliSense secured up to $13 million from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis. This significant investment follows positive results from an initial efficacy trial (Phase IIa), demonstrating improved lung function in approximately 70% of patients. This indicates strong external validation and critical financial backing for the company's lead product, signaling accelerated progress towards commercialization and addressing a high-need patient population.
Log in to access full profile ›Company Intelligence Q&A
- What is the most recent funding SpliSense received?
- In June 2026, SpliSense secured up to $13 million in funding from the Cystic Fibrosis Foundation to advance its Phase 2b study of SPL84 for cystic fibrosis.
- What regulatory designation did SpliSense receive for SPL84 in May 2024?
- In May 2024, SpliSense received FDA Fast Track Designation for SPL84 for the treatment of cystic fibrosis.
- What was the outcome of the Phase 2 study for SPL84 announced in September 2025?
- In September 2025, SpliSense reported positive results from its Phase 2 study of SPL84 in cystic fibrosis.
- Which organization granted SpliSense an early PRIME designation for SPL84 in March 2026?
- In March 2026, SpliSense was granted EMA early PRIME designation for SPL84 in cystic fibrosis.
- When did SpliSense receive Orphan Drug Designation for SPL84-23-1 from the FDA and EMA?
- In January 2022, SpliSense announced that the FDA and EMA granted Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis.